• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    11/27/24 8:30:20 AM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email
    false 0001140859 0001140859 2024-11-26 2024-11-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of Earliest Event Reported):   November 26, 2024

     

    Cencora, Inc.
    __________________________________________
    (Exact name of registrant as specified in its charter)

     

    Delaware   1-16671   23-3079390
    (State or other jurisdiction   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification No.)
             

    1 West First Avenue
    Conshohocken, PA

         

     

    19428-1800

    (Address of principal executive offices)       (Zip Code)

     

    Registrant’s telephone number, including area code:   (610) 727-7000

     

    __________________________________________
    Not Applicable
     

    Former name or former address, if changed since last report

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of exchange on which
    registered
    Common stock COR New York Stock Exchange (NYSE)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company     ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ¨

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    Term Loan Facility for Proposed Acquisition of Retina Consultants of America

     

    On November 26, 2024, Cencora, Inc., a Delaware corporation (the “Company”), entered into a Term Credit Agreement, among the Company, the lenders party thereto and Bank of America, N.A., as administrative agent (the “Term Credit Agreement”). The Company entered into the Term Credit Agreement in connection with the previously announced proposed acquisition (the “Acquisition”) of Retina Consultants of America. The Term Credit Agreement provides for a senior unsecured term facility of $1.5 billion (the “Term Loan”), which matures three years from the date on which the Term Loan is drawn under the Term Credit Agreement (such date on which the Acquisition is consummated and the Term Loan is drawn, the “Closing Date”). The proceeds of the Term Loan will be used to pay a portion of the cash consideration in respect of the Acquisition and to pay fees and expenses incurred in connection with the Acquisition. The funding under the Term Credit Agreement is subject to closing conditions, including the consummation of the Acquisition.

     

    The Term Loan will bear interest at a rate equal to either an adjusted Term SOFR rate plus an applicable margin or an alternate base rate plus an applicable margin, in each case based on the Company’s public debt ratings by Standard & Poor’s Ratings Services, Moody’s Investors Service, Inc. and Fitch, Inc. Such applicable margins range from 87.5 basis points to 137.5 basis points over the adjusted Term SOFR rate and 0 basis points to 37.5 basis points over the alternate base rate, in each case, as determined in accordance with the provisions of the Term Credit Agreement. In addition, commencing on March 5, 2025, an undrawn commitment fee will begin to accrue on the aggregate amount of unused commitments under the Term Credit Agreement. The Company has the right to prepay the Term Loan at any time, in whole or in part and without premium or penalty (other than, if applicable, any breakage costs). The Company may also choose to reduce its commitments under the Term Loan at any time.

     

    The Term Credit Agreement contains certain affirmative and negative covenants, and includes limitations on indebtedness of subsidiaries, liens, fundamental changes, asset sales and a covenant requiring compliance with a financial leverage ratio not to exceed 3.75 to 1.00 as of the last day of any fiscal quarter (which may be increased to 4.00 to 1.00 at the Company’s election as of the last day of the fiscal quarter during which the Closing Date occurs). The covenants contained in the Term Credit Agreement are substantially similar to the covenants contained in the Company’s existing $2.4 billion multi-currency senior unsecured revolving credit facility (the “Existing Revolving Credit Facility”). The Term Credit Agreement also contains customary events of default (which are in some cases subject to certain exceptions, thresholds and grace periods) including, but not limited to, nonpayment of principal and interest, failure to perform or observe covenants, breaches of representations and warranties and certain bankruptcy-related events.

     

    As previously disclosed, in connection with the Acquisition, the Company obtained $3.3 billion in bridge financing commitments to fund the cash purchase price of the Acquisition. As a result of entering into the Term Credit Agreement, such bridge financing commitments have been automatically reduced by $1.5 billion, which is the amount of the commitments under the Term Credit Agreement, to $1.8 billion.

     

    The foregoing description of the Term Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the Term Credit Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

     

    364-Day Revolving Credit Facility

     

    On November 26, 2024, the Company entered into a Credit Agreement (the “Credit Agreement”), among the Company, the lenders party thereto and Bank of America, N.A., as administrative agent, pursuant to which the Company obtained a $1.0 billion senior unsecured revolving credit facility (the “Revolving Credit Facility”).

     

    Borrowings under the Revolving Credit Facility will be available on and after the Closing Date and will mature on the date that is 364 days after the Closing Date (the “Revolving Facility Maturity Date”). Borrowings outstanding on the Revolving Facility Maturity Date will mature and be payable on such date, or, at the option of the Company, on the first anniversary of the Revolving Facility Maturity Date. The Company’s option to extend the maturity of any borrowings outstanding on the Revolving Facility Maturity Date is subject to customary conditions and the payment of an extension fee on such outstanding borrowings.

     

    Interest on borrowings under the Revolving Credit Facility will accrue at a rate equal to either an adjusted Term SOFR rate plus an applicable margin or an alternate base rate plus an applicable margin, in each case based on the Company’s public debt ratings by Standard & Poor’s Ratings Services, Moody’s Investors Service, Inc. and Fitch, Inc. Such applicable margins range from 87.5 basis points to 137.5 basis points over the adjusted Term SOFR rate and 0 basis points to 37.5 basis points over the alternate base rate, in each case, as determined in accordance with the provisions of the Credit Agreement. The Company has agreed to pay facility fees to maintain the availability under the Revolving Credit Facility at specified rates based on its public debt ratings, ranging from 5.0 basis points to 12.5 basis points, annually, of the total commitments of the lenders thereunder. The Company has the right to prepay borrowings under the Revolving Credit Facility at any time, in whole or in part and without premium or penalty (other than, if applicable, any breakage costs), provided that the amount of any such prepayment meets certain minimum thresholds. The Company may also choose to reduce its commitments under the Revolving Credit Facility at any time.

     

     

     

     

    The Company may use the funds provided under the Revolving Credit Facility for general corporate purposes of the Company and its subsidiaries. The Revolving Credit Facility contains affirmative and negative covenants that are substantially similar to those contained in the Existing Revolving Credit Facility and the Term Credit Agreement, including limitations on indebtedness of subsidiaries, liens, fundamental changes, asset sales and a covenant requiring compliance with a financial leverage ratio not to exceed 3.75 to 1.00 as of the last day of any fiscal quarter (which may be increased to 4.00 to 1.00 at the Company’s election as of the last day of the fiscal quarter during which the Closing Date occurs). The Revolving Credit Facility contains certain representations, warranties and events of default (which are, in some cases, subject to certain exceptions, thresholds and grace periods) including, but not limited to, non-payment of principal and interest, failure to perform or observe covenants, breaches of representations and warranties and certain bankruptcy-related events.

     

    The foregoing description of the Revolving Credit Facility does not purport to be complete and is qualified in its entirety by reference to the Credit Agreement, which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated by reference herein.

     

    Certain of the lenders under the Revolving Credit Facility and the Term Credit Agreement, and their affiliates, have various relationships with the Company and have in the past provided, and may in the future provide, investment banking, commercial banking, derivative transactions and financial advisory services to the Company and its affiliates in the ordinary course of business for which they have received and may continue to receive fees and commissions. In particular, BofA Securities, Inc., an affiliate of Bank of America, N.A., Citigroup Global Markets Inc., an affiliate of Citibank, N.A., J.P. Morgan Securities LLC, an affiliate of JPMorgan Chase Bank, N.A., Wells Fargo Securities, LLC, an affiliate of Wells Fargo Bank, N.A., and BNP Paribas Securities Corp., an affiliate of BNP Paribas, have served as joint book-running managers, and certain affiliates of the other lenders have served as underwriters, in connection with past senior note offerings by the Company, and such affiliates may serve similar roles in future securities offerings by the Company. In addition, certain of the lenders serve various roles in connection with a $1.45 billion receivables securitization facility to which the Company’s subsidiaries, AmerisourceBergen Drug Corporation, ASD Specialty Healthcare, LLC, and Amerisource Receivables Financial Corporation (“ARFC”), are a party and pursuant to which accounts receivables are sold on a revolving basis to ARFC, a special purpose entity. MUFG Bank, Ltd. serves as administrator and a purchaser under the program. Certain of the other lenders or their affiliates also serve as lenders or purchasers under the securitization facility. Furthermore, certain of the lenders serve various roles in connection with the Existing Revolving Credit Facility. Specifically, JPMorgan Chase Bank, N.A. serves as administrative agent under the Existing Revolving Credit Facility and certain of the other lenders or their affiliates also serve as lenders under the Existing Revolving Credit Facility.

     

    Item 2.03. Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth in Item 1.01 above is hereby incorporated by reference into this Item 2.03.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    Number
    Description
    10.1 Term Credit Agreement, dated as of November 26, 2024, among Cencora, Inc., the lenders party thereto and Bank of America, N.A., as Administrative Agent.
    10.2 Credit Agreement, dated as of November 26, 2024, among Cencora, Inc., the lenders party thereto and Bank of America, N.A., as Administrative Agent.
    104 Cover Page Interactive Data File (formatted as inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     Cencora, Inc.
        
    November 27, 2024By: /s/ James F. Cleary
     Name: James F. Cleary
     Title: Executive Vice President and Chief Financial Officer

     

     

     

    Get the next $COR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    1/29/2026$400.00Equal-Weight → Overweight
    Morgan Stanley
    1/22/2026$440.00Hold → Buy
    Jefferies
    12/9/2025$400.00Overweight
    Barclays
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    More analyst ratings

    $COR
    SEC Filings

    View All

    Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    2/18/26 7:34:15 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    2/13/26 4:36:38 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    2/11/26 5:00:08 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Covetrus and MWI Animal Health to Merge

    Combination of companion animal distribution, production animal distribution and technology platforms will make animal healthcare more accessible and affordable Transaction unites complementary businesses to deliver innovative, efficient solutions and expertise across the entire animal health ecosystem Deal values MWI at an enterprise value of $3.5 billion. Cencora to receive cash proceeds of $1.25 billion and $800 million of preferred equity while retaining a non-controlling common equity stake of 34.3% in the combined company Cencora reaffirms fiscal 2026 financial guidance Cencora (NYSE:COR) and Covetrus, a global animal health technology and services company, today announce

    2/18/26 7:00:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Closes $3.0 Billion Senior Notes Offering

    Cencora, Inc. (NYSE:COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the "2029 Notes"), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the "2030 Notes"), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the "2033 Notes"), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due February 13, 2036 (the "2036 Notes") and $500 million aggregate principal amount of its 5.650% Senior Notes due February 13, 2056 (the "2056 Notes" and, together with the 2029 Notes, the 2030 Notes, the 2033 Notes and the

    2/13/26 4:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056

    Cencora, Inc. (NYSE:COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the "2029 Notes"), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the "2030 Notes"), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the "2033 Notes"), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due February 13, 2036 (the "2036 Notes") and $500 million aggregate principal amount of its 5.650% Senior Notes due February 13, 2056 (the "2056 Notes" and, together with the 2029 Notes, the 2030 Notes, the 2033 Notes and the 2036 Notes, the "Notes"

    2/10/26 5:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cencora upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Cencora from Equal-Weight to Overweight and set a new price target of $400.00

    1/29/26 6:57:57 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora upgraded by Jefferies with a new price target

    Jefferies upgraded Cencora from Hold to Buy and set a new price target of $440.00

    1/22/26 8:20:03 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Barclays initiated coverage on Cencora with a new price target

    Barclays initiated coverage of Cencora with a rating of Overweight and set a new price target of $400.00

    12/9/25 8:43:35 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Mauch Robert P. exercised 3,762 shares at a strike of $86.09 and sold $1,350,332 worth of shares (3,762 units at $358.94) (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    2/24/26 4:04:51 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    President & CEO Mauch Robert P. sold $479,160 worth of shares (1,333 units at $359.46), decreasing direct ownership by 2% to 65,393 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    2/20/26 4:00:23 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    SEC Form 3 filed by new insider Cooper Ellen

    3 - Cencora, Inc. (0001140859) (Issuer)

    1/30/26 3:59:47 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    5/29/24 4:02:27 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Financials

    Live finance-specific insights

    View All

    Cencora Reports Fiscal 2026 First Quarter Results

    Revenue of $85.9 billion for the First Quarter, a 5.5% Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.87 and Adjusted Diluted EPS of $4.08 Adjusted Operating Income Guidance Raised to Growth of 11.5% to 13.5% Adjusted Diluted EPS Guidance Range Reaffirmed at $17.45 to $17.75 for Fiscal 2026 Company Completes Acquisition of OneOncology Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in th

    2/4/26 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 4, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access t

    1/6/26 4:30:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results

    Revenue of $83.7 Billion for the Fourth Quarter, a 5.9 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $(1.75) and Adjusted Diluted EPS of $3.84 Revenue of $321.3 Billion for Fiscal Year 2025, a 9.3 Percent Year-Over-Year Increase Fiscal Year 2025 GAAP Diluted EPS of $7.96 and Adjusted Diluted EPS of $16.00 Company increases its quarterly dividend by 9 percent Company raises its long-term guidance expectations Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally a

    11/5/25 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Leadership Updates

    Live Leadership Updates

    View All

    Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

    Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Mr. Durcan will succeed Steven H. Collis, who has served as Cencora's Chairman since 2016 and previously served as Cencora's Chief Executive Officer from 2011 until 2024. As previously disclosed, Mr. Collis was elected to serve as Executive Chairman of the Board effective October 1, 2024 for a period of one year. "Our Board is confident that Mark's public company CEO and board experience, along with his strategic planning and technological innovation experience, make him the right person to step into t

    8/27/25 4:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Expands Enterprise Leadership Team with Two Senior Appointments

    Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

    11/4/24 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

    The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo

    9/14/21 2:00:00 PM ET
    $AXS
    $COR
    $POR
    Property-Casualty Insurers
    Finance
    Other Pharmaceuticals
    Health Care

    $COR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cencora Inc.

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    11/14/24 1:22:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cencora Inc.

    SC 13D/A - Cencora, Inc. (0001140859) (Subject)

    8/5/24 6:43:49 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by CoreSite Realty Corporation (Amendment)

    SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)

    7/12/21 8:29:18 AM ET
    $COR
    Other Pharmaceuticals
    Health Care